AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00543959
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.
Trial: NCT01077921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
Trial: NCT00271713
Drug: ibandronate, calcium and vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or
Trial: NCT00271713
Drug: placebo,calcium and vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily
Trial: NCT00847509
Drug: [F-18]FLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The individual doses of \[F-18\]FLT contain a maximum of 10 mCi. The single IP dose is administered to the study subject approximately 30 to 60 minutes prior to the start of PET imaging.
Trial: NCT01089517
Drug: E10030 plus Lucentis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a month intravitreal injection
Trial: NCT04631276
Drug: TS-091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received single-dose of 0.1, 0.2, 0.4, 1, 5, 12.5 and 25 mg of TS-091 (tablets or drug substance powder)
Trial: NCT02300194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
Trial: NCT02653417
Drug: RAD1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD1901
Trial: NCT01635127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constituent of canakinumab
Trial: NCT02600819
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg FDC tablets administered orally once daily
Trial: NCT02600819
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/200/25 mg FDC tablets administered orally once daily
Trial: NCT02736890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive subcutaneous placebo injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
Trial: NCT04277923
Drug: Lipofundin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the lipid of all-in-one is less than 4g/kg.d
Trial: NCT00676715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to ocrelizumab administered as IV infision in Cycle 1 Day 1.
Trial: NCT01369836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of matched placebo.
Trial: NCT00991211
Drug: Standard chemotherapy CHOP + Ritiximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
Trial: NCT00499616
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00499616
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03336437
Drug: Estradiol vaginal ring
RxNorm normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol 2mg vaginal ring
Trial: NCT02901184
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with Spironolactone tablets on top of standard care
Trial: NCT03847506
Drug: Ezetimibe/Rosuvastatin
RxNorm normalized name: EZETIMIBE/ROSUVASTATIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Candesartan cilexetil 8 mg placebo
Trial: NCT00942994
Drug: Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)~HCTZ capsule (12.5 mg, 25mg)
Trial: NCT00429728
Drug: GW876008
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00865540
Drug: prednisolone acetate 1%
RxNorm normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop every 8h two days before surgery
Trial: NCT00865540
Drug: ketorolac tromethamine 0.4%
RxNorm normalized name: KETOROLAC TROMETHAMINE 0.4% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop every 8h two days before surgery
Trial: NCT00865540
Drug: nepafenac 0.1%
RxNorm normalized name: NEPAFENAC 0.1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop every 8h two days before surgery
Trial: NCT03052400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02314637
Drug: Teneligliptin + Sulfonylurea
RxNorm normalized name: sulfanilylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teneligliptin for 52 weeks in combination with sulfonylurea
Trial: NCT04126278
Drug: Barbotage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as per standard of care
Trial: NCT01697514
Drug: LY2940680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule administered orally.
Trial: NCT01697514
Drug: LY2940680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder administered orally (may be sprinkled on soft food).
Trial: NCT02230670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02592057
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF tablets administered orally once daily based on approved prescribing information
Trial: NCT01713101
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01396447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied in capsules.
Trial: NCT03493217
Drug: ICP-022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug product is a white, round, uncoated tablet.
Trial: NCT03002025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo to JNJ-64304500 as SC injection.
Trial: NCT03081962
Drug: Bundle
RxNorm normalized name: Refill Bundle 7 Large Office KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.
Trial: NCT02922686
Drug: Placebo (for phenoxymethylpenicillin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-encapsulation of phenoxymethylpenicillin will be performed by the manufacturer of the investigational medicinal products such that placebo and active phenoxymethylpenicillin are identical in size, shape, colour and smell, and are packaged in identical bottles
Trial: NCT00437294
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, daily, 21-day cycles until progressive disease
Trial: NCT00437294
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m\^2, BID, days 1-14 of each 21-day cycle until progressive disease
Trial: NCT01646268
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo will receive matching placebo patches
Trial: NCT02933684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in pill form.
Trial: NCT03364270
Drug: PET/CT Imaging with [F-18] RGD-K5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET Imaging/scan with \[F-18\] RGD-K5, PET Imaging/scan with RGD-K5, PET Imaging/scan with K5
Trial: NCT04364984
Drug: Angiotensin converting enzyme inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: routine drug intake
Trial: NCT04364984
Drug: Direct renin inhibitor
RxNorm normalized name: DIRECT RENIN INHIBITOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: routine drug intake
Trial: NCT01307189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo diskus inhalation powder, once daily
Trial: NCT02105961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile 0.9percent sodium chloride solution
Trial: NCT00461591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravesical dose of placebo instilled into the bladder post-TURBT
Trial: NCT02467426
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intraarterial infusion of cisplatin and mithoxantrone
Trial: NCT02660489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03248791
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.
Trial: NCT00852839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match oromucosal formulation of 552-02
Trial: NCT00961909
Drug: RO5095932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cohorts receiving multiple ascending doses, sc once weekly for 4 weeks
Trial: NCT00961909
Drug: RO5095932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose titration to target dose, sc once weekly for 6 weeks
Trial: NCT00961909
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc once weekly for 4 weeks
Trial: NCT01528839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00322517
Drug: SU014813
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg capsule/day for 6 cycle of 21 days
Trial: NCT00008034
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01711424
Drug: OPTIVE PLUS®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
Trial: NCT01700387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the onabotulinumtoxinA + placebo group will receive:~Week 1: placebo 25 mg qhs Week 2: placebo 25 mg bid Week 3: placebo 25 mg q am + placebo 50 mg qhs Week 4: placebo 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period.
Trial: NCT02481453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator: placebo
Trial: NCT01473602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by SC injection
Trial: NCT00531427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal system (placebo) applied for 7-day wear
Trial: NCT00006289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tabs b.i.d.
Trial: NCT00006289
Drug: Neurotropin
RxNorm normalized name: neurotrophin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tabs b.i.d.
Trial: NCT03254511
Drug: Chemotherapeutic Combinations
RxNorm normalized name: ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are going to receive weekly chemotherapy (paclitaxel \[50 mg/m2\] plus carboplatin \[area under the carve=2\]).
Trial: NCT02110459
Drug: POL7080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT04120519
Drug: thalidomide combined with dexamethasone and cyclophosphamide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TCD
Trial: NCT02439489
Drug: BKM120-CARBO
RxNorm normalized name: CARBO ANIMALIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Carboplatin will be delivered intravenously at AUC 5 on day 1 every 3 weeks at each dose level of BKM120. Should dose level 3 be completed, carboplatin will be given at AUC 6 and BKM120 at 100 mg.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity
Trial: NCT00692263
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
Trial: NCT03190941
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Trial: NCT00859352
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets during 14 consecutive days.
Trial: NCT02605460
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.
Trial: NCT01783756
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03645434
Drug: AZD8871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.
Trial: NCT03645434
Drug: Anoro® Ellipta®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.
Trial: NCT03678649
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
Trial: NCT02154152
Drug: Homoeopathic Medicine causticum 200c
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02422199
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00758199
Drug: Bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks
Trial: NCT00758199
Drug: Prednisolone Acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
Trial: NCT00003496
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Recurrent or Extensive-Stage Small Cell Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT02529553
Drug: LY3076226
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02605122
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age- and weight-based dosing as appropriate per sites standard of care.
Trial: NCT00667108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo 30 minutes prior to bedtime
Trial: NCT02923921
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX Alone
Trial: NCT04606329
Drug: LuminoMark inj.(Conc. for fluorescence)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
Trial: NCT04606329
Drug: Charcotrace Inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection Charcotrace Inj. about 0.3\~1mL once in this study.
Trial: NCT02558413
Drug: BTA-C585 oral capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTA-C585; Single ascending doses from 50 mg to 800 mg
Trial: NCT02558413
Drug: BTA-C585 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses to match 50 to 800 mg BTA-C585 capsules
Trial: NCT01250145
Drug: LY333334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch
Trial: NCT01250145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch
Trial: NCT04475042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04384081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT04316091
Drug: neoadjuvant chemotherapy+SPIONs/SMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection of SPIONs, followed by SMF, combined with conventional neoadjuvant chemotherapy
Trial: NCT01587807
Drug: GSK1995057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled dose (volume based on cohort)
Trial: NCT01587807
Drug: LPS
RxNorm normalized name: ALPS LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg
Trial: NCT01587807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)
Trial: NCT00947687
Drug: PUR003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
Trial: NCT00947687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05764707
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will received 1000mg of intravenous acetaminophen within 30 minutes of skin closure.
Trial: NCT05764707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will received 1000mg of normal saline within 30 minutes of skin closure.
Trial: NCT03223519
Drug: Comboprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days
Trial: NCT03223519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for oral solution administered TID for 3 days
Trial: NCT03223519
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Powder for oral solution administered TID for 3 days
Trial: NCT04155580
Drug: ASTX660
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for oral administration
Trial: NCT04155580
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration
Trial: NCT01485172
Drug: placebo monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo as monotherapy in Parkinson's disease
Trial: NCT02428283
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil 1 μg/kg was injected before skin incision.
Trial: NCT00050362
Drug: Rofecoxib and Bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00495014
Drug: GSK376501
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00495014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02049606
Drug: CENATONE tablet
RxNorm normalized name: BENTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Tablets once a day
Trial: NCT02907632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution: 1 drop per kg of placebo 15 minutes before lactation with identical presentation appearance, taste and color than Metoclopramide. Duration: Until the child completes 40 weeks of post menstrual age.
Trial: NCT03143933
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02594254
Drug: C16G2 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial peptide
Trial: NCT00133549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo administered in a volume of 0.5 ml intramuscularly.